Missing Information
  • A System Error Has Occured:0177 - Failed to Load All Sections.
Form Type:  SC 13G
Filing Date:  1/5/2018 
CIK:  0001604464 
Address:  611 GATEWAY BLVD
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-278-8930 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.77 (2.11%)  
Trade Time: 
Jan 18  
Market Cap: 
Trade ATRA now with 

© 2019  
Description of Business
Atara Biotherapeutics is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Atara's most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus, or EBV, associated post-transplant lymphoproliferative disorder, or EBV+ PTLD, who have failed rituximab, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma, or NPC.